Computational biology company Evogene Ltd. EVGN will release its financial results for the full year and fourth quarter of 2021 on March 10, 2022. On the day of the announcement, the company's management will host a conference call to discuss the results at 09:00 a.m. EST.
Evogene established three unique technological engines, MicroBoost AI, ChemPass AI and GeneRator AI. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (Microboost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). The company uses its technological engines to develop products through subsidiaries and with strategic partners. Evogene's main subsidiaries utilize the technological engines to develop novel products as follows: human microbiome-based therapeutics by Biomica Ltd., medical cannabis by Canonic Ltd., ag-chemicals by AgPlenus and ag-biologicals by Lavie Bio Ltd.
Price Action
Evogene shares traded 1.63% higher at $1.25 per share at the time of writing Tuesday morning.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.